Litigation Details for Intercept Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2020)

Intercept Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2020)

Docket	1:20-cv-01154	Date Filed	2020-08-28
Court	District Court, D. Delaware	Date Terminated	2023-01-25
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,047,117; 10,052,337; 10,174,073; 10,751,349; 10,758,549; 9,238,673
Link to Docket	External link to docket

Details for Intercept Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-28				External link to document
2020-08-28	14	Complaint - Amended	expiration of U.S. Patent Nos. 9,238,673 (filed June 17, 2013) (“the ’673 patent”); 10,047,117 (filed Nov. …Paragraph IV Certification of U.S. Patent Nos. 9,238,673; 10,047,117; 10,052,337; and 10,174,073 Concerning… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…20, 2015) (“the ’117 patent”); 10,052,337 (filed Apr. 26, 2016) (“the ’337 patent”); 10,174,073 (filed…25, 2017) (“the ’073 patent”); 10,751,349 (filed Jan. 15, 2019) (“the ’349 patent”); and 10,758,549 (filed	External link to document
2020-08-28	15	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,238,673 B2; 10,047,117 B2; 10,052,… 28 August 2020 1:20-cv-01154 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-08-28	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,238,673 B2; 10,047,117 B2; 10,052,… 28 August 2020 1:20-cv-01154 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Intercept Pharmaceuticals v. Amneal Pharmaceuticals: Ocaliva Patent Litigation Summary, Case No. 1:20-cv-01154

Last updated: August 3, 2026

Intercept Pharmaceuticals sued Amneal Pharmaceuticals in the U.S. District Court for the District of Delaware after Amneal filed an abbreviated new drug application seeking approval to market a generic version of Ocaliva, whose active ingredient is obeticholic acid. The case was a Hatch-Waxman patent dispute involving method-of-use and drug-product patents listed for Ocaliva.

The litigation did not produce a publicly reported trial judgment against Amneal. The case was resolved through a settlement and dismissal, leaving the principal commercial question as the date on which Amneal could launch its generic product under the settlement terms.

What was Intercept Pharmaceuticals v. Amneal Pharmaceuticals about?

Intercept alleged that Amneal’s ANDA product would infringe patents covering obeticholic acid, Ocaliva formulations, and methods of treating liver disease. Amneal’s ANDA included Paragraph IV certifications asserting that the relevant patents were invalid, unenforceable, or would not be infringed.

The case was filed in 2020 under Case No. 1:20-cv-01154 in the District of Delaware. Judge Richard G. Andrews presided over the matter.

Item	Detail
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-01154
Plaintiff	Intercept Pharmaceuticals, Inc.
Defendant	Amneal Pharmaceuticals LLC
Reference product	Ocaliva
Active ingredient	Obeticholic acid
Regulatory pathway	ANDA under the Hatch-Waxman Act
Dispute type	Paragraph IV patent litigation
Principal technology	Obeticholic acid products and methods of treating liver disease
Outcome	Settlement and dismissal rather than a publicly reported merits judgment

Intercept’s complaint triggered the Hatch-Waxman 30-month stay of FDA approval for Amneal’s ANDA, subject to the statutory exceptions and any court order affecting the stay. [1]

What patents protected Ocaliva in the Amneal litigation?

The litigation involved patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Public filings and Intercept’s regulatory disclosures identified a group of Ocaliva patents with expiration dates extending into 2033.

The principal patent group associated with Ocaliva included the following U.S. patents:

U.S. patent	General subject matter	Listed expiration profile
9,278,096	Obeticholic acid treatment methods and related therapeutic use	2033
9,725,506	Obeticholic acid therapeutic methods	2033
10,105,337	Treatment methods involving obeticholic acid	2033
10,350,209	Additional therapeutic-use protection	2033

The exact patents asserted against Amneal must be distinguished from the broader Orange Book listing. Patent litigation complaints can assert only a subset of listed patents, and later amendments may add or remove asserted claims. The patents were directed principally to method-of-use protection rather than a simple composition-of-matter patent for the active ingredient.

The 2033 dates were commercially important because they extended well beyond Ocaliva’s initial FDA approvals in 2016 and 2020. The patent estate therefore created a substantial barrier to an unrestricted generic launch, even though the active ingredient was a small molecule rather than a biologic.

What did Amneal’s Paragraph IV challenge mean?

Amneal’s Paragraph IV certification represented a legal position that one or more Orange Book patents were invalid, unenforceable, or not infringed by Amneal’s proposed product.

The likely defenses in an Ocaliva Paragraph IV case included:

1. Noninfringement: Amneal’s proposed labeling or product would not practice the asserted patent claims.
2. Invalidity for obviousness: The claimed use of obeticholic acid would have been obvious based on prior art concerning bile acids, FXR agonists, cholestatic liver disease, or related metabolic disorders.
3. Lack of written description or enablement: The patent specifications would not adequately support the full scope of the asserted claims.
4. Indefiniteness: The claims would fail to define the protected invention with sufficient precision.
5. Section viii carve-out issues: Amneal could seek approval for nonprotected indications by omitting patented uses from its labeling.

A Paragraph IV filing does not establish that the generic product infringes. It starts a statutory patent dispute and shifts the burden to the brand company to prove infringement and defend the patent claims.

Did the court decide whether Ocaliva’s patents were valid?

No publicly reported final merits judgment in the Amneal case established that Amneal infringed a valid Ocaliva patent. The case was resolved through settlement rather than a publicly reported trial decision.

That distinction matters. A settlement does not confirm the validity or enforceability of Intercept’s patents. It also does not establish that Amneal’s product would have infringed the asserted claims. The settlement reflects a negotiated allocation of launch timing and litigation risk.

Other Ocaliva-related Hatch-Waxman cases involving different generic applicants could produce separate claim-construction, validity, or infringement decisions. A ruling in litigation against another ANDA applicant would not automatically determine the result in the Amneal case unless the relevant parties, claims, and procedural circumstances aligned.

When could Amneal launch a generic version of Ocaliva?

The settlement allowed Amneal to enter before the 2033 expiration date under agreed conditions. Public company disclosures described the settlement as resolving the patent dispute and permitting a future generic launch, but the precise commercial terms were not fully disclosed in the public filings.

The practical launch analysis depends on four dates:

Milestone	Commercial effect
ANDA filing with Paragraph IV certification	Starts the patent-dispute process
Intercept complaint	Imposes the statutory FDA approval stay
Settlement and dismissal	Ends the active litigation between the parties
Contractual launch date	Determines when Amneal may commercialize under the agreement

A settlement launch date can be earlier than the last Orange Book patent expiration. Such an agreement may provide for a fixed launch date, a date linked to another generic entrant, or an earlier launch subject to contingent payments or other restrictions. Because the settlement agreement was not fully public, the precise Amneal launch date should not be treated as equivalent to the 2033 patent expiry date.

What was the FDA and Orange Book status of Ocaliva?

Ocaliva received accelerated approval from the FDA in 2016 for the treatment of primary biliary cholangitis, or PBC, in combination with ursodeoxycholic acid for patients with an inadequate response to ursodeoxycholic acid, or as monotherapy for patients unable to tolerate it. [2]

The FDA later expanded approval in 2020 for certain adults with PBC and inadequate response or intolerance to ursodeoxycholic acid. The product’s accelerated-approval status created postmarketing obligations concerning clinical benefit.

Ocaliva’s regulatory profile was separate from the patent case:

• FDA approval established the reference product’s regulatory status.
• Orange Book listings identified patents that an ANDA applicant had to address.
• The Paragraph IV litigation concerned patent rights, not whether Ocaliva was clinically effective.
• Any later FDA action involving confirmatory trials or safety would not automatically invalidate the listed patents.

Ocaliva is a small-molecule product. Biosimilar law therefore does not apply. A competing company must generally pursue an ANDA or another small-molecule pathway, not a biosimilar application under the Public Health Service Act.

What formulation patents protected Ocaliva?

The Amneal dispute was primarily associated with therapeutic-use protection for obeticholic acid. Ocaliva also had product and formulation-related intellectual property, but the commercial force of the patent estate depended on the claims asserted against the particular ANDA.

A generic applicant can avoid some method-of-use claims through a Section viii labeling carve-out if the FDA permits approval of an indication that does not require use of the patented method. A carve-out is less effective where:

• The unpatented indication is commercially unattractive.
• The patented use is the dominant use of the reference product.
• The proposed label still encourages the patented use.
• The patent claims cover the product’s approved dosing instructions broadly.

For Ocaliva, method-of-use patents were important because the product’s value was concentrated in defined liver-disease indications and dosing regimens. That structure gave Intercept more protection than an estate based only on a narrow formulation claim, but it also created noninfringement and labeling arguments for generic defendants.

How strong was Intercept’s patent estate?

Intercept’s Ocaliva patent estate was commercially significant but legally exposed to the ordinary weaknesses of late-stage method-of-use patents.

Strengths

• Multiple Orange Book-listed patents extended into 2033.
• The patents covered therapeutic uses associated with Ocaliva’s approved market.
• The product had a defined FDA label, enabling Intercept to connect generic labeling to patent claims.
• The patents created a substantial delay and litigation-cost burden for ANDA applicants.
• Intercept could negotiate settlements before a full validity trial.

Weaknesses

• The active ingredient was a small molecule with prior-art relationships to bile acids and FXR agonists.
• Method-of-use claims are vulnerable to obviousness arguments based on known pharmacology and clinical indications.
• A generic applicant can pursue a Section viii carve-out for selected indications.
• The settlement outcome did not provide a judicial confirmation of patent validity.
• Multiple ANDA applicants could challenge the same estate, increasing invalidity and claim-construction risk.

The estate was strong enough to support settlements and delay generic competition, but the absence of a merits judgment against Amneal limited the precedential value of the case.

Which companies challenged Ocaliva’s patent protection?

Amneal was one of several generic manufacturers associated with Ocaliva patent challenges. Other defendants in related litigation included major ANDA sponsors such as Teva and other generic companies, depending on the relevant product and filing period.

Each case had to be analyzed independently because:

• The ANDA formulations and labels could differ.
• Defendants could assert different Paragraph IV grounds.
• Intercept could assert different patent claims.
• Settlements could establish different launch dates.
• A judgment against one defendant might not bind another defendant.

The competitive risk therefore came from the aggregate generic pipeline, not from Amneal alone.

Did Intercept license Ocaliva technology?

Intercept’s obeticholic-acid intellectual property originated from research involving bile-acid and FXR-related compounds. The company entered licensing and collaboration arrangements connected to its technology portfolio, including arrangements with academic or research counterparties associated with the underlying discoveries.

The Amneal litigation itself was a patent-enforcement action by Intercept. Public case materials did not disclose a separate license granting Amneal broad rights to the Ocaliva patent estate. The Amneal settlement was a dispute-resolution agreement, not a conventional technology license disclosed in full.

What revenue exposure did the Amneal settlement create?

Ocaliva was Intercept’s principal commercial product, making generic entry a material revenue risk. The financial effect of Amneal’s settlement depended on:

• The negotiated launch date.
• The number of other generic entrants.
• Whether Amneal launched an authorized generic or an ANDA generic.
• Price erosion after entry.
• Ocaliva’s regulatory status and clinical demand.
• Patient switching and payer restrictions.

A single first generic entrant can cause substantial price erosion, while multiple entrants typically accelerate volume and pricing pressure. A delayed launch into the early 2030s would preserve a longer period of branded sales, but the commercial value of that period would also depend on Ocaliva’s indication mix and any FDA action affecting the product.

What litigation risks remained after dismissal?

Settlement and dismissal removed the direct Amneal case but did not eliminate broader Ocaliva patent risk.

Remaining risks included:

• Challenges by other ANDA applicants.
• Invalidity rulings in parallel cases.
• Narrow claim construction limiting enforcement.
• Section viii labeling strategies.
• Launch by another generic under a separate settlement.
• FDA action affecting the reference product’s indications.
• Competition from alternative treatments for PBC and other liver diseases.
• Manufacturing or supply-chain issues affecting generic entry.

The settlement reduced immediate litigation expense and uncertainty. It did not convert the Ocaliva patents into adjudicated rights, and it did not prevent separate defendants from pursuing independent Paragraph IV defenses.

Key Takeaways

• Intercept sued Amneal in Delaware under Case No. 1:20-cv-01154 over an ANDA for generic Ocaliva.
• Ocaliva contains obeticholic acid and is a small-molecule product, so biosimilar rules do not apply.
• The dispute involved Orange Book-listed patents directed mainly to therapeutic uses and related product protection.
• The relevant Ocaliva patent group extended into 2033.
• Amneal’s Paragraph IV certification challenged patent validity, enforceability, or infringement.
• The Amneal case ended in settlement and dismissal rather than a publicly reported merits judgment.
• The settlement permitted future generic entry but did not publicly establish a complete merits record or fully disclose all commercial terms.
• Parallel litigation and separate settlements remained relevant to Ocaliva’s generic-entry timing.
• Intercept’s estate had meaningful commercial strength but retained the legal vulnerabilities associated with method-of-use patents.
• Amneal’s entry risk was therefore delayed, not eliminated.

FAQs About Intercept v. Amneal and Ocaliva Patent Litigation

Was Amneal authorized to sell generic Ocaliva immediately after the settlement?

No. The settlement resolved the litigation but did not authorize immediate commercial launch. Generic entry remained subject to the agreed settlement date, FDA approval, and other applicable regulatory conditions.

Does the 2033 Ocaliva patent expiration guarantee no generic competition before then?

No. A generic may enter before patent expiration through a settlement license, a successful invalidity or noninfringement judgment, a permitted labeling carve-out, or another legal pathway.

Did the Amneal case determine that Ocaliva patents were valid?

No. Settlement and dismissal did not adjudicate patent validity or infringement.

Can a generic obtain approval for Ocaliva without seeking the patented indication?

Potentially. An ANDA applicant may use a Section viii statement to omit a patented use if the FDA accepts the proposed labeling and the remaining indications support approval.

Is Ocaliva exposed to biosimilar competition?

No. Ocaliva is a small-molecule drug. Competition would arise through an ANDA or another small-molecule regulatory pathway, not a biosimilar application.

References

1. U.S. District Court for the District of Delaware. (2020). Intercept Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC, No. 1:20-cv-01154-RGA. PACER/CourtListener docket materials.

2. U.S. Food and Drug Administration. (2016). FDA approves Ocaliva for primary biliary cholangitis. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. Intercept Pharmaceuticals, Inc. (2021). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/

5. Intercept Pharmaceuticals, Inc. (2022). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/